← Back to Analyst Consensus 
AMRX Buy
Amneal Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 3, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Sep 23, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Sep 17, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 9, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Aug 3, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jul 15, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| May 20, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 17, 2026 | UBS | initiate | — → Buy | — | 54% |
| Mar 2, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $15 | 53% |
| Oct 31, 2025 | Piper Sandler | reiterate | Overweight → Overweight | $13 | 54% |
| Sep 16, 2025 | JP Morgan | maintain | Overweight → Overweight | $14 | 55% |
| Mar 3, 2025 | Barclays | maintain | Overweight → Overweight | $11 | 53% |
| Feb 24, 2025 | JP Morgan | upgrade | Neutral → Overweight | $12 | 55% |
| Nov 11, 2024 | Piper Sandler | maintain | Overweight → Overweight | $11 | 54% |
| Oct 2, 2024 | Truist Securities | maintain | Buy → Buy | $12 | 55% |
| Sep 6, 2024 | JP Morgan | upgrade | Underweight → Neutral | $9 | 55% |
| Aug 13, 2024 | Barclays | maintain | Overweight → Overweight | $10 | 53% |
| Aug 12, 2024 | Truist Securities | maintain | Buy → Buy | $10 | 55% |
| May 6, 2024 | Goldman Sachs | maintain | Buy → Buy | $8 | 54% |
| May 6, 2024 | Truist Securities | reiterate | Buy → Buy | $9 | 55% |
| Mar 21, 2024 | Piper Sandler | maintain | Overweight → Overweight | $8 | 54% |
| Mar 4, 2024 | Goldman Sachs | maintain | Buy → Buy | $6.25 | 54% |
| Jan 29, 2024 | Barclays | maintain | Overweight → Overweight | $8 | 53% |
| Nov 8, 2023 | Truist Securities | maintain | Buy → Buy | $7 | 55% |
| Sep 6, 2023 | Truist Securities | reiterate | Buy → Buy | $6 | 55% |
| Aug 7, 2023 | Piper Sandler | maintain | Overweight → Overweight | $5 | 54% |
| Aug 7, 2023 | Truist Securities | maintain | Buy → Buy | $6 | 55% |
| Aug 7, 2023 | Barclays | maintain | Overweight → Overweight | $5 | 53% |
| May 8, 2023 | Piper Sandler | maintain | — → Overweight | $3 | 54% |
| Mar 29, 2023 | Truist Securities | maintain | — → Buy | $4 | 55% |
| Mar 10, 2023 | Barclays | maintain | — → Overweight | $4 | 53% |
| Mar 3, 2023 | Goldman Sachs | maintain | — → Buy | $3 | 54% |
| Mar 3, 2023 | BMO Capital | maintain | — → Market Perform | $4 | 53% |
| Aug 8, 2022 | Goldman Sachs | maintain | — → Buy | $4 | 54% |
| May 12, 2022 | Goldman Sachs | maintain | — → Buy | $4.5 | 54% |
| Mar 8, 2021 | Goldman Sachs | upgrade | Sell → Buy | $6.5 | 54% |
| Dec 14, 2020 | Guggenheim | upgrade | Neutral → Buy | $0 | 52% |
| Nov 9, 2020 | SVB Leerink | maintain | — → Market Perform | $5.5 | — |
| Oct 9, 2020 | Piper Sandler | maintain | — → Overweight | $6 | 54% |
| Jul 27, 2020 | Goldman Sachs | initiate | — → Sell | $4 | 54% |
| May 13, 2020 | SunTrust Robinson Humphrey | maintain | — → Buy | $5 | — |
| May 12, 2020 | Guggenheim | upgrade | Sell → Neutral | $0 | 52% |
| May 12, 2020 | SVB Leerink | maintain | — → Market Perform | $4 | — |
| Apr 2, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $3 | 54% |
| Feb 27, 2020 | SunTrust Robinson Humphrey | maintain | — → Buy | $5 | — |
| Jan 2, 2020 | RBC Capital | maintain | — → Sector Perform | $4 | 55% |
| Dec 12, 2019 | Raymond James | downgrade | Outperform → Market Perform | $0 | 53% |
| Nov 12, 2019 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Nov 11, 2019 | BMO Capital | maintain | — → Market Perform | $4 | 53% |
Price Target Trend
Jun 1, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days